FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval
Filed with ASX · · 2 pages · English
Story so far
Earlier from Mesoblast
- FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
- Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
- Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
- Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
- Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
Later from Mesoblast
- Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
- Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
- Successful Commercial Launch of Ryoncil®
- Mesoblast Financial Results and Corporate Update Webcast
- Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast